US stock futures edge lower after S&P 500 hits record high; PCE data in focus
Investing.com - Qualigen Therapeutics reported on Tuesday second quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Qualigen Therapeutics announced earnings per share of $-0.100 on revenue of $1.44M. Analysts polled by Investing.com EPS of $-0.140 on revenue of $1.62M.
Qualigen Therapeutics 's are down 79% and is trading at $0.221 , still down 92.92% from its 52 week high of $3.12 set on Tuesday, November 23, 2021.
Qualigen Therapeutics shares gained 1.98% to trade at $0.221 in intra-day trade the report.
Qualigen Therapeutics follows other major Healthcare sector earnings this month
Qualigen Therapeutics's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar